Identification and Quantification of Drugs, Metabolites, Drug Metabolizing Enzymes, and Transporters

<p>Part I: Techniques for Identifying and Quantifying Drugs and Metabolites<br>1. Bioanalysis of Small and Large Molecule Drugs, Metabolites, and Biomarkers by LC-MS<br>2. Recent advances in mass spectrometric and other analytical techniques for the identification of drug metabolites <br>3. High-resolution mass spectrometry-based data acquisition and data mining technologies for detecting and characterizing drug metabolites and herbal medicine components<br>4. Metabolite Generation and Metabolite Characterization by NMR<br>5. Application of SFC for bioanalysis<br>6. AMS in drug development: Exploring the current utility of AMS and future opportunities for Absolute Bioavailability and ADME investigations</p> <p>Part II: Drug Metabolism Enzymes, Transporters and Drug-Drug Interaction<br>7. Using in vitro methods to determine P450s responsible for metabolism and discrimination from other oxidative pathways<br>8. Evaluation of the clearance mechanism of non-CYP enzymes mediated drug metabolism and DDI as a victim drug　<br>9. In vitro Characterization and In Vitro to In Vivo Predictions of Drug-Drug Interactions<br>10. Role of Transporters in drug disposition and Drug-drug Interactions<br>11. Mechanisms and Clinical Relevance of Pharmacokinetic-based Clinical Drug-drug Interactions for Drugs Recently Approved by the U.S. Food and Drug Administration　<br>12. Quantifying drug metabolism enzymes and transporters by LC-MS/MS proteomics <br>13. Protein Drug-Drug Interactions for Disease Modifying Modalities</p> <p>Part III: Strategy Related to Drug Metabolism and Safety<br>14. Metabolites in safety testing (MIST)<br>15. The Use of Stable Isotopes in Drug Metabolism Studies　<br>16. Assessment of Stereoselectivity in Pharmacology, Toxicology and Drug Metabolism <br>17. Progress of De-Risking Strategies for Drug-Induced Liver Injury (DILI) In the Last Two Decades<br>18. Predictive and Translational Models for Renal Drug Safety Evaluation<br>19. Immunogenicity: An Introduction to Its Role in the Safety and Efficacy of Biotherapeutics</p> <p>Part IV: Translational Sciences<br>20. Application of Genetically-Modified Rodent Models in Drug Discovery and Development　for Translation of Clinical ADME Properties<br>21. Advances in CRISPR Technologies Enable Novel in vitro Tools for ADME Studies<br>22. In vitro-In vivo Extrapolation of Human Hepatic and Renal Clearance<br>23 The Role of Mathematical Modeling in Translational Science <br>24. PK/PD Driven Starting and Effective Human Dose Determination for Immuno-Oncology Drugs</p>